Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Condition:   Pediatric Growth Hormone Deficiency Interventions:   Drug: MOD-4023;   Drug: Somatropin Sponsor:   Opko Biologics Not yet recruiting - verified October 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials